

FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B




FIGURE 4A




FIGURE 4B




FIGURE 5A




FIGURE 5B




FIGURE 6A




FIGURE 6B




FIGURE 7A




FIGURE 7B




FIGURE 8A




FIGURE 8B




FIGURE 9

**Weight of Human Colon Adenocarcinoma (HT-29) in CD-1
Nude Mice Treated with Combination Therapy**




FIGURE 10




FIGURE 11

Growth of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice




FIGURE 12




FIGURE 13





FIGURE 14

Weight of Human Prostate Carcinoma (PC-3)
in SCID Mice

A



B





FIGURE 15

Weight of Human Prostate Carcinoma(DU145)
in SCID Mice

A



B




FIGURE 16

Weight of Human Melanoma (A2058) in CD-1 Nude Mice






FIGURE 17

Weight of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice



Growth of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice




FIGURE 18





FIGURE 19

A Growth of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice



B Weight of Human Pancreatic Carcinoma (BxPC-3) In CD-1 Nude Mice





FIGURE 20

Growth of Human Cervix Epitheloid Carcinoma
(HeLa S3-HU-Resistance) in SCID Mice

A



Weight of Human Cervix Epitheloid Carcinoma
(HeLa S3-HU-Resistance) In SCID Mice

B





FIGURE 21

Weight of Human Cisplatin-Resistant Breast Adenocarcinoma
Implanted at the Fat Pad of SCID Mice




Statistical Analysis: P value
Saline : Cisplatin 0.0834
Saline : Taxol <0.0001
Saline : SEQ ID NO:1 <0.0001
SEQ ID NO:1 : Cisplatin 0.0007
SEQ ID NO:1 : Taxol 0.9547


FIGURE 22

Growth Of Human Breast Cancer (MDA-CDDP-S4) In CB-17 SCID Mice Treated With Taxol, SEQ ID NO:1, and Taxol+SEQ ID NO:1 (Orthotopical transplant)


A



B



C




SEQ ID NO:1: Taxol P=0.0133
SEQ ID NO:1: SEQ ID NO:1+Taxol P=0.0003
Taxol : SEQ ID NO:1+Taxol P<0.0001

FIGURE 23

Weight of Human Taxol-Resistant Breast Adenocarcinoma (MDA-MB435-To.1) Implanted at the Fat Pad of SCID Mice

A



B





FIGURE 24

Growth of Human Breast Adenocarcinoma (MDA-MB435-To. 1)
in SCID Mice

A



Weight of Human Breast Adenocarcinoma (MDA-MB-435-To. 1)
in SCID Mice

B





FIGURE 25

Growth of Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice

A



Weight of Human Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice

B





FIGURE 26

Growth of Human Multi-Drug Resistance Colon Adenocarcinoma (LS513) In SCID Mice



Weight of Human Colon Multi-Drug Resistance Carcinoma (LS513) In SCID Mice




FIGURE 27

>gi|4557844|ref|NM_001034.1| Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA

```
CCCAGGCGCAGCCAATGGGAAGGGTCGGAGGCATGGCACAGCCAATGGGAAGGGCGGGCACCAAAGCC  
AATGGGAAGGGCGGGAGCGCGCGCGGGAGATTAAAGGCTGCTGGAGTGAGGGGTGCCCCGTGAC  
CCTGTCCTCAGCGTCTGCTGGCTCTGCTCGCTCGCTGCCCTCCATATGCTCTCCCTCCGTG  
TCCCGCTCGGCCCATCAGGACCGCAGCTGAGCTCGCCGCTGAAGGGGCTCAGCTTGGTCA  
CAAGGAGAACACGCCGCCGCGCCCTGAGCGGGACCGCAGCTGGGAGCAAGACCGCGAGGAGATCTC  
CAGGAGCACCAGGAGCCAAAATCAAAGCAGCTGCCCGCGCTGGAGGATGAGCCGCTGAGAGAAA  
ACCCCGCGCGCTTGTCACTTCCCCATCGACTACCATGATACTGGCAGATGATAAGAAGGAGAGGC  
TTCTCTTGGACCGCCGAGGAGGTGACCTCTCCAAGGACATTCAAGCACTGGGAATCCCTGAAACCGAG  
GAGAGATATTATATCCATGTTCTGGCTTCTTGCAGCAAGCGATGGCATAGTAAATGAAAATTCG  
TGGAGCGATTAGCCAAGAAGTTCAGATTACAAGGCCGCTGTTCTATGGCTTCCAAATTGCCATGGA  
AAACATACATTCTGAAATGATAGTCCTTATTCAGACACTTACATAAAAGATCCAAAGAAAGGAAATT  
CTCTTCATGCAATTGAAACGATGCCCTGTGTCAGAAGAAGGAGACTGGGCTTGCCTGGAAATTGGGG  
ACAAAGAGGCTACCTATGGTGAACGTGTTGAGCAGTGGCAGTGGAAAGGCAATTCTTCCGGTTC  
TTTGCCTCGATAATTCTGGCTCAAGAAACGAGGACTGATGCCCTGAGCTCAATTCTAAATGAACTTATT  
AGCAGAGATGAGGGTTTACACTGTGATTTCGCTTGCCCTGATGTTCAAACACCTGGTACACAAACATCGG  
AGGAGAGAGTAAGAGAAATAATTCAATGCTGTTGGATAGAACAGGAGTCCCTCACTGAGGCCCTGGC  
TGTGAAGCTATTGGGATGAATTGCACTCTAATGAAGCAATACATTGAGTTGTGGCAGACAGACTTATG  
CTGGAACTGGGTTTAGCAAGGTTTCAAGTAGAGAAGAACCCATTGACTTTATGGAGAAATTTCACTGG  
AAGGAAGACTAACTTCTTGGAGAAGAGTAGGGCAGTACAGGGATGGGAGTGTCAAGTCCAAAC  
AGAGAATTCTTACCTTGGATGCTGACTCTAAATGAACTGAGATGTGCCCTTACTTGGCTGATT  
TTTCCATCTATAAGAAAATCAGCTGAAGTGTACCAACTAGCCACACCATGAATTGTCCGTAATGT  
TCATTAACAGCATCTTAAACTGTGTAAGCTACCTCACAAACGAGTCCCTGTGTTTATGCTGGTACT  
ATCACCTTGGCAGAAGGCCCTGGCTGACTTACCATAGCAGTGAACATGGCAGTCTTGGCTTAA  
AAGTGAGGGGTGACCCTTAGTGAGCTTAGCACAGGGGATTAACAGTCCCTTAAACAGCACAGCCAGT  
TAAAAGATGCAGCCTCACTGCTTCAACGCAATTAAATGTTACTTAAATATAAACCTGGCACTTACA  
AACAAATAAAACATTGTTGACTCACGCCCGGATAATAGCTGATTATTGGTTCTACACCAAATA  
CATCTCCCTGACCAACTAATGGGAGCCAATTCAACATCAACTAAGTGACTAAAGTAAGTAAACTTGTGTA  
GACTAAGCATGTAATTAAAGTTTAAATGAAATTGTTAAACCAACTTAAAGTCAGT  
CCTGTGTTACCTAGATAATTAGTCAGTGGTCCAGATAGAACAGGTTGTTTATCTTGTGGCTT  
GTGAGTGCTGGATTCTGCCCCCTCTGAGTAGAGTGTGGGATAAAGGAATCTCAGGGCAA  
GGAGCTTCTAAGTAAACACTAGAAATTAGGGGTGATCTGGCTTCAATGTGTGAGAAGGCCGTT  
CATTTATTCTCACTGTATTCTTCCCTCACGCTGTTGATGAGAAAAAAATTCTTGTGAGAAGGTTTCAAT  
GTGGGAGCTAAGGTAGTATTGAAAAATTCAAGTCATCCCTTAAACAAAATGATCCACCTAAGATCTTGC  
CCTGTTAAGTGGTGAATCAACTAGAGGTGGTCCACAGTGTCTTCAAGTGTCTTGTGAGAAG  
TAGGTTGTGAGTTAAATTCAATTATATTACTATGTCGTGTTAAATCAGAAATTTTTATTATCTATGTT  
CTCTAGATTACCTGTAGTTCAAAAAAAAAAAAAAA
```

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.